oral drugs in multiple sclerosis

Journal club ,[object Object],[object Object],[object Object]

Oral drugs in multiple sclerosis ,[object Object],[object Object],[object Object],[object Object]

fingolimod ,[object Object],[object Object],[object Object],[object Object],[object Object]

fingolimod ,[object Object],[object Object],[object Object],[object Object]

Fingolimod -effects ,[object Object],[object Object],[object Object],[object Object],[object Object]

Study design and randomisation ,[object Object],[object Object],[object Object],[object Object]

Inclusion criteria ,[object Object],[object Object],[object Object],[object Object],[object Object]

Exclusion criteria ,[object Object],[object Object],[object Object]

Study Procedures and End Points ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object]

Secondary endpoints ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Statistical analysis ,[object Object],[object Object],[object Object],[object Object]

Study Population ,[object Object],[object Object],[object Object],[object Object]

conclusion ,[object Object],[object Object],[object Object]

Mode of action ,[object Object],[object Object]

Patients ,[object Object],[object Object],[object Object]

Study design ,[object Object],[object Object],[object Object],[object Object],[object Object]

Study design ,[object Object],[object Object],[object Object]

conclusions ,[object Object],[object Object],[object Object]

Critical analysis ,[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object]

Empfohlen